This trial will compare the effectiveness of BHV3000 to a placebo for subjects with Trigeminal Neuralgia that haven't responded to other treatments. The pain scale will be used to measure the difference between the two-week treatment phases.
1 Primary · 5 Secondary · Reporting Duration: From Baseline to End of Randomization Phase, up to 5 weeks.
60 Total Participants · 2 Treatment Groups
Primary Treatment: BHV3000 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: